Differential micro RNA expression in PBMC from multiple sclerosis patients

Area of Science:

• Neuroimmunology
• Molecular Biology
• Genetics

Background:

• Gene expression differences are observed in Multiple Sclerosis (MS) patients, particularly during disease relapse.
• MicroRNAs (miRNAs), a class of gene expression modulators, are increasingly recognized for their role in disease pathogenesis.

Purpose of the Study:

• To investigate the role of miRNAs in Multiple Sclerosis (MS), with a specific focus on the relapse stage.
• To identify specific miRNAs and their target genes associated with MS relapse and remission.

Main Methods:

• Analysis of 364 miRNA expression patterns in peripheral blood mononuclear cells (PBMCs) from MS patients (relapse, remission) and healthy controls.
• Validation of differentially expressed miRNAs in an independent sample set.
• Quantitative PCR (qPCR) to study the expression of predicted miRNA target genes.
• Construction of gene interaction networks for co-expression and multivariate analysis.

Main Results:

• Two miRNAs, hsa-miR-18b and hsa-miR-599, were found to be significantly different in MS patients during relapse.
• One miRNA, hsa-miR-96, showed differential expression potentially linked to MS remission.
• Target genes of hsa-miR-96 are implicated in immunological pathways (e.g., Interleukin signaling) and Wnt signaling.

Conclusions:

• miRNA expression is important in the molecular mechanisms underlying Multiple Sclerosis (MS).
• Specific miRNAs (hsa-miR-18b, hsa-miR-599, hsa-miR-96) may serve as biomarkers for MS relapse and remission.
• miRNAs represent a potential new therapeutic avenue and biomarker target for MS.